Lung Cancer Rx

Data presented at ASCO 2026 further underscore the importance of identifying which patients with early-stage NSCLC are eligible for targeted therapies. Jamie E. Chaft, MD, discusses results from the LIBRETTO, CROWN, and EA5142 trials with LungCancerRx hosts Aakash Desai, MD, MPH, Eric K. Singhi, MD, and Fawzi F. Abu Rous, MD.

Ferdinandos Skoulidis, MD, PhD, discusses data on KRAS- mutated NSCLC from ASCO 2026 with Aakash Desai, MD, MPH, Fawzi F. Abu Rous, MD, and Eric K. Singhi, MD.

Given recent advances, where do things stand for neoadjuvant therapy in patients with NSCLC? The panel discusses current considerations and what important questions may soon be answered. Patrick Forde MBBCh, PhD, a thoracic medical oncologist at Johns Hopkins University in Baltimore, Maryland, and professor of immuno-oncology at Trinity College Dublin discusses current multidisciplinary approaches...

From screening to treatment, myths and misperceptions about lung cancer present challenges for physicians and patients. From setting the record straight on surgical approaches to setting higher expectations for treatment outcomes, the LungCancerRx panel tackles key questions currently faced in practice.

Despite notable recent advances in lung cancer treatment, early diagnosis remains a challenge. From problems with screening criteria to changes in disease demographics, the LungCancerRx panel explains why the only solution is “education, education, education.”

To cap off the first year of the LungCancerRx podcast, cohosts Aakash Desai, MD, MPH; Eric K. Singhi, MD; and Fawzi F. Abu Rous, MD, share how they first came together and what they see as their mission for the series moving forward. “I think we want to stop the gatekeeping of information,” Dr. Singhi explained.

In this episode of LungCancerRx, Eric Singhi, MD, Aakash Desai, MD, MPH, and Fawzi F. Abu Rous, MD, welcome Julia Rotow, MD to the conversation. “I think we’ve been very lucky, in the world of EGFR-mutated lung cancer, that it has gotten so complicated,” explains  Julia Rotow, MD , clinical director of the Lowe Center for Thoracic Oncology and director of clinical research at the Dana-Farber Cance...

In this episode of LungCancerRx, the experts talk about key trials presented at the World Conference on Lung Cancer, and the rapidly shifting landscape in lung cancer treatment, which now can be treated as multiple different diseases. Cohost Eric Singhi, MD, is joined by Bruna Pellini, MD, Antonio Calles, MD, and Stephen Liu, MD.

In this episode of LungCancerRx, the experts talk about the FLAURA2 and HARMONi data presented at the World Conference on Lung Cancer and what the findings mean for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Recorded onsite in Barcelona, Spain, cohost Eric Singhi, MD, from Houston, Texas, is joined by Bruna Pellini, MD, from Moffitt Cancer Center and Research Institute in Tampa...

In this episode of LungCancerRx, Eric Singhi, MD, Aakash Desai, MD, MPH, and Fawzi F. Abu Rous, MD, welcome back Christine M. Lovly, MD, PhD, to talk about the complexities of treating advanced EGFR-positive NSCLC. Dr. Lovely shares how she talks with patients about the latest data and recent trials.

As oncologists stand on “the cutting edge” of neoadjuvant treatment for EGFR-mutated lung cancer, how should they conduct complex conversations with patients? Christine M. Lovly, MD, PhD, joins hosts Aakash Desai, MD, MPH; Eric K. Singhi, MD; and Fawzi F. Abu Rous, MD, for an honest discussion about current challenges.

When it comes to treatment decisions for patients with EGFR-mutated non-small cell lung cancer, “the most important conversations are not the data-driven ones, they are the relational ones,” says patient advocate  Jill Feldman . In the second episode of the LungCancerRx video podcast, cohosts  Fawzi F. Abu Rous, MD , a thoracic medical oncologist at Henry Ford Health in Detroit; Eric K. Singhi, MD...

In the first episode of the LungCancerRx video podcast, cohosts Eric K. Singhi, MD, a thoracic oncologist in Houston;  Aakash Desai, MD, MPH , an assistant professor at the University of Alabama at Birmingham’s O'Neal Cancer Center; and  Fawzi Abu Rous, MD , a thoracic medical oncologist at Henry Ford Health in Detroit; are joined by patient advocate  Jill Feldman . They talk about her experience...